Coming Soon

HPTN 083 - A Phase 2b/3 Double Blind Safety and Efficacy Study of Injectable Cabotegravir Compared to Daily Oral Tenofovir Disoproxil Fumerate/Emtricitabine (TDF/FTC), For Pre-Exposure Prophylaxis in HIV-Uninfected Cisgender Men and Transgender Women who have Sex with Men

  • Question: To evaluate the safety and efficacy of the injectable agent, cabotegravir (CAB LA), for pre exposure prophylaxis (PrEP) in HIV-uninfected cisgender men and transgender women who have sex with men (MSM and TGW).
  • Population: HIV-uninfected men who have sex with men (MSM) and transgender women (TGW) at risk for acquiring HIV infection, ages 18 or older
  • Medication: Cabotegravir 600mg long-acting injectable vs. Truvada 300/200mg daily oral medication
  • Duration: up to 4 years
  • Call: Becky Straub, RN 919-843-9975 or Miriam Chicurel-Bayard, RN 919-843-9922

M14-730 A Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Adults with Chronic Hepatitis C Virus (HCV) Genotype 1 - 6 Infection and Human Immunodeficiency Virus-1 (HIV-1) Co-Infection (EXPEDITION-2)

  • Question: The primary objectives of this study are to compare the SVR12 rates (12-week sustained virology response) of 8 or 12 weeks of treatment with ABT-493/ABT-530 combination in HCV genotype 1 - 6 infected subjects with HIV-1 confection and to assess the safety of treatment with the combination regimen ABT-493/ABT-530 in HCV genotype 1 - 6 infected subjects with HIV-1 co-infection with or without cirrhosis
  • Population: Adults ≥ 18 years, with chronic HCV GT 1 - 6 infection and HIV-1 co-infection and HIV-1 co-infection without cirrhosis or with compensated cirrhosis, who are either HCV treatment-naïve or prior treatment-experienced 
  • Medication: 8 or 12 weeks of ABT-493 (an NS3/4A PI)/ABT-530(an NS5A inhibitor)
  • Duration: 36 weeks
  • Call: Donna Pittard 919-843-6512